Australia markets open in 4 hours 32 minutes

Scopus BioPharma Inc. (SCPS)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0021+0.0010 (+90.91%)
As of 11:06AM EDT. Market open.

Scopus BioPharma Inc.

420 Lexington Avenue
Suite 300
New York, NY 10170
United States
212 479 2513
https://scopusbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees13

Key executives

NameTitlePayExercisedYear born
Mr. Ira Scott GreenspanSenior Advisor & Director200kN/A1959
Mr. Robert J. GibsonVice Chairman, Secretary & Treasurer200kN/AN/A
Dr. Alan D. Horsager Ph.D.President?of?Immuno-Oncology and President & CEO of Duet BioTherapeuticsN/AN/A1973
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Corporate governance

Scopus BioPharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.